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Purpose: To review and critique the current state of liquid biopsy in pHGG.
Materials and Methods: Published literature was reviewed for articles related to liquid biopsy in pediatric glioma and adult glioma with
a focus on high-grade gliomas.
Results: This review discusses the current state of liquid biomarkers of pHGG and their potential applications for liquid biopsy
development.
Conclusions: While nascent, the progress toward identifying circulating analytes of pHGG primes the field of neuro-oncoogy for liquid
biopsy development.
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Aggressive brain tumors, such as pediatric high-grade
gliomas (pHGGs), are the number one cause of cancer-
related deaths during childhood (defined as age 0-14 years
in the United States).1 Despite decades of clinical trials
with aggressive multimodal therapy, disease recurrence isican Society for Radiation Oncology. This is an open access article under
).
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a combined 5-year survival rate of 17%.2 Clinical ad-
vances in central nervous system (CNS) tumors are
hampered by inaccurate or incomplete measures of dis-
ease owing to sensitive neuroanatomical location, risk of
serial biopsy, and limitations in imaging technologies. In
addition, a definitive noninvasive biomarker for disease
measurement is lacking. The development of liquid bi-
opsies is critical to advance the clinical management of
these tumors, with the hope of directing long-term disease
control.
Although rare, pHGGs comprise 8% to 12 % of
childhood brain tumors with an annual incidence of 0.85
per 100,000 in the United States.1 These tumors are
responsible for almost 13,000 years of potential life lost
annually.3 Children typically present with headaches,
seizures, vision changes, vomiting, or other neurologic
deficits related to specific tumor location. Standard eval-
uation includes magnetic resonance imaging (MRI) and,
in most cases, a neurosurgical intervention (i.e., biopsy or
resection) for a histologic and molecular diagnosis.
Although pHGGs are distinct diseases from adult high-
grade gliomas,4 treatment rationales in clinical trials are
often shaped by the literature on adult gliomas.5 Child-
hood cancer consortiums, such as the Children’s
Oncology Group, have conducted numerous clinic trials
(e.g., ACNS0126, ACNS0423)6,7 to improve outcomes
for this population. However, current management con-
sists of maximal surgical resection followed by radiation
therapy with concurrent and adjuvant alkylator therapy. A
notable exception is diffuse intrinsic pontine glioma
(DIPG), which is an unresectable tumor with no known
curative treatment. Radiation therapy is used to extend the
symptom-free period, but offers minimal survival
advantage.8
Regardless of location and subgroup, patients with
pHGGs are commonly monitored with regular clinical
examinations and surveillance imaging. Despite the
best available therapy, recurrence is near inevitable, and
most cases recur locally within the radiation field and
diffuse spread occurs in up to a third of patients.9
Clinical advances for this patient population are
hampered by the rarity of the disease, sensitive tumor
location, risks10 of serial biopsy, disease heterogeneity,
limitations of drug delivery (blood-brain barrier), and
inaccurate or incomplete measures of disease status.
Over the past 50 years, despite hundreds of clinical
trials, the dismal outcomes for children with pHGG
have not significantly changed.
Although clinical advances are stagnant, remarkable
advances have been made in the past decade in the un-
derstanding of the bimolecular basis of pHGG. Large
cooperative working groups (eg, International Society of
Pediatric Oncology Europe),11 patient registries, tissue
banking and sharing, and open access data sets (eg, whole
genome sequencing, whole exosome sequencing,methylation analysis12) have yielded robust opportunities
to study these rare childhood tumors. Interrogations of
well-annotated large patient cohorts have revealed the
diversity of pHGG with key genetic and epigenetic events
associated with distinct age of onset, neuroanatomic lo-
cations, and prognosis, allowing for biologically and
clinically relevant subgrouping.13
The discovery of novel driver mutations in genes
encoding histone 3 K27M (H3K27M) and G34V/R
(H3G34R/V) in pHGG implicate chromatin remodeling,
developmental signaling pathways, and gene expression
mechanisms in disease pathogenesis.14-16 These unique
recurrent mutations underscore fundamental differences
between pediatric and adult high-grade gliomas. The
World Health Organization classification of CNS tumors
now includes some molecularly defined subsets (eg,
H3K27M and isocitrate dehydrogenase 1 [IDH1] muta-
tions, which are mutually exclusive and prognostically
relevant).17,18 H3K27M-mutant pHGGs confer a worse
prognosis compared with wild type, whereas IDH1 mu-
tants (although rare in the pediatrics setting) carry a better
prognosis than IDH wild type.19
These observations have ignited efforts to further
molecularly subclassify this heterogeneous group of dis-
eases into biologically and prognostically relevant groups
through initiatives from the Consortium to Inform Mo-
lecular and Practical Approaches to CNS Tumor
Taxonomy.20
Ongoing efforts to dissect and stratify pHGGs continue
to yield new insights into pediatric gliomagenesis and
identify novel therapeutic opportunities. Leveraging the
distinct molecular biology driving pHGG has led to the
first study in human clinical trials in the pediatric setting
(eg, NCT02960230). However, more than novel thera-
peutics are needed to improve patient outcomes (eg,
inaccurate measures of disease threaten determination of
therapeutic efficacy).
Currently few tools exist for the serial measurement of
disease in pHGGs, which are predominately neuro-
imaging and clinical examination and have limited
sensitivity and specificity. There is a critical need for
minimally invasive biomarkers in pHGG. A real-time
readout of tumor dynamics would fundamentally change
the care of children with these aggressive tumors. In this
review, we highlight the current efforts toward minimally
invasive analytes of pHGG and evaluate their overall
importance in improving the outcome for children with
pHGGs.
Imaging advances in pediatric high-grade
gliomas
Gadolinium-based contrast agent (GBCA)eenhanced
MRI remains the standard of care for the diagnosis,
operative planning, and assessment of the therapeutic
Figure 1 Dilemma of monitoring pseudoprogression with gadolinium-based contrast agent magnetic resonance imaging. Gadolinium-
based contrast agent magnetic resonance imaging after Stupp protocol therapy in isocitrate dehydrogenase-wild type glioblastoma
demonstrates the challenge of prospectively diagnosing treatment response. Minimal enhancement after chemoradiation therapy (arrow)
increases over time (middle, yellow and purple boxes) but eventually resolves without intervention (right, green box). Retrospectively,
this is interpreted as neuroinflammation; however, response assessment in neuro-oncology criteria would not differentiate from disease
recurrence necessitating changes in therapy or biopsy.
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logical differences in tumor biology are notable dissimi-
larities that could affect the imaging assessment of pHGG
compared with adult tumors. Warren et al. recognized the
potential limitations of applying adult-based response
assessment in neuro-oncology23 criteria to pediatric brain
tumors and proposed pediatric-centric imaging response
criteria.24 The response assessment in pediatric neuro-
oncology working group has identified the need for
pediatric-centric imaging criteria owing to the heteroge-
neous group of pediatric brain tumors, relative paucity of
clinical trials, and lack of standard metrics to establish
radiographic tumor responses to therapy or survival.
To address this current gap in knowledge, the response
assessment in pediatric neuro-oncology working group
has set the goal of proposing optimal endpoints and study
designs, develop a consensus on the radiologic assess-
ment for clinical trials involving children with brain tu-
mors, and better define response to reflect therapeutic
activity in pHGG.24 Jaspan et al. published methodolog-
ical perspectives on the use of morphologic and physio-
logical MRI response metrics in a randomized phase 2
trial of newly diagnosed pHGG treated with temozolo-
mide and irradiation with or without bevacizumab
(HERBY25).
The HERBY study was designed to assess treatment
response to inform future clinical trials in pHGG from a
biological and imaging perspective. Morphologic imaging
response metrics included T2 and GBCA-enhanced T1-
weighted sequences. In addition, diffusion- and perfusion-
based metrics were assessed and included in the
estimation of pHGG response assessments. The rationale
behind this was that, compared with morphologic se-
quences alone, a multimodal MRI approach may provide
a more informed biology-based approach to establishing
treatment response. Despite initiatives to incorporate
physiological sequences into pHGG clinical trial response
assessments, GBCA-MRI remains the standard of care.The use of T1-weighted GBCA-MRI as a metric of
therapeutic response assessments in pHGGs is problem-
atic. Functionally, GBCA enhancement is a measure of
neurovascular unit disruption. As such, GBCA does not
specifically localize regions of tumor regrowth. Biologi-
cally, tissue enhancement on T1-weighted MRI is a factor
of the leakage and pooling of GBCA from the vascular
space through the neurovascular unit into the brain tumor
interstitial space.25 The limitations of GBCA-MRI
in evaluating therapeutic responses in adult gliomas is
well established (Fig 1). The nonspecificity of GBCA
enhancement for the differentiation of tumor regrowth
from treatment-related inflammation necessitates serial
follow-up imaging or invasive surgical sampling to
establish disease status.
Furthermore, in certain clinical contexts (e.g., bev-
acizumab therapy), the absence of GBCA enhancement
does not preclude the presence of active tumor growth.26
In either context, this clinical dilemma may delay defin-
itive therapy for disease recurrence and potentially
decrease the potential for a response to that therapy. As
such, the development of a blood-based biomarker for
therapeutic responses to complement imaging would be
advantageous in this population.Progress toward liquid biopsy
Measures of disease status must capture more than
anatomic presence, and those capable of assessing path-
ophysiologic evolution of disease hold the potential to
better inform the care of patients with pHGG. The liquid
biome, including blood, cerebrospinal fluid (CSF), and
urine, provides a rich, noninvasive biosource to interro-
gate for tumor-associated biomaterials. Biomaterials, such
as tumor-associated proteins, nucleic acids, exosomes,
and cells, hold the potential to act as analytes for disease
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monitoring, and recurrence surveillance.
Robust discovery and exploratory liquid biopsy in-
vestigations are ongoing in the adult setting, and
emerging work is underway in the pediatric sphere, as
reviewed by Bonner et al.27 To advance the care of pa-
tients with pHGG, the field must leverage advancing
detection technologies to develop sensitive circulating
disease analytes that are highly tumor specific and are
thereby clinically actionable. Herein the progress toward
liquid biopsy in pHGG is critically reviewed and
compared with liquid biopsy in adult high-grade glioma.
Protein biomarkers: Powerful peptides
Protein biomarkers are distinct intact peptides that can
be differentially regulated in the setting of disease,
including alterations in secretion, shedding, and loss from
cells. They are detected in blood, urine, cerebral spinal
fluid, and generally stable peptides that therefore can
provide an objective, quantitative, and noninvasive mea-
sure of disease.28 The first biomarker was reported in
1848 with the discovery of the lambda light chain (Bence
Jones proteins), which are detected with a urinalysis in
75% of patients with multiple myeloma.29
From this initial discovery, the field of protein bio-
markers has grown into the most clinically robust
biomaterial for use in cancer monitoring and detection.
CA-125, CA19-9, HER2/NEU, and Fibrin/FDP are all
blood-based protein biomarkers approved by the US Food
and Drug Administration for use in the detection, moni-
toring, or prognosis of ovarian, pancreatic, breast, and
colorectal cancer, respectively.30 Although there are
currently no FDA-approved biomarkers for high-grade
gliomas, multiple candidate proteins are under
exploration.
Protein biomarkers in adult high-grade gliomas
Proteins are the most investigated biomaterial in adult
glioma, including studies in serum, plasma, CSF, and
urine. Proteins related to angiogenesis, such as vascular
endothelial growth factor, have been reported to be more
elevated in patients with gliomas compared with con-
trols.31 A variety of proteins related to cell invasion and
tissue remodeling, such as matrix metalloproteinases
(MMP) and tissue inhibitors of metalloproteinases, have
been identified as potential biomarkers. For example,
levels of MMP-2, MMP-9, and tissue inhibitor of
metalloproteinase-1 could be used to detect the presence
of gliomas from healthy controls and distinguish low-
from high-grade glioma.32
Many other proteins, including YKL-40, osteopontin,
glial fibrillary acid protein, 2-hydroxyglutarte, and growth
factors such as hepatocyte placental, insulin binding, andbasic fibroblast have been investigated. However, to date
no clinically actionable protein biomarkers have
emerged.33Protein biomarkers in pediatric high-grade
gliomas
Proteins hold promise as biomarkers in pHGG, but
their value remains largely to be realized. Investigations
into proteins of interest in adult glioma have not been
substantiated potential importance for pHGG, including
vascular endothelial and basic fibroblast growth factors,
where the levels between control, benign disease, and
malignant disease were very similar.34 Tumor-associated
proteins have been explored in a handful of pediatric
CNS tumors, including cyclophilin A and DDAH1, which
were associated with disease presence compared with
healthy controls.35
A proteomic analysis of CSF from pediatric CNS tu-
mors, including pHGG, revealed 6 proteins able to
discriminate metastatic cases from controls.36 Exploiting
the unique drivers of pHGG holds promise for the
detection of meaningful biomarkers. Investigations into
the posttranslational modification of proteins in the liquid
biome may prove a valuable strategy given the known
pHGG driver mutations in epigenetic mechanisms, such
as chromatin remodeling. Much opportunity exists to
discover protein biomarkers that exploit unique features
of pHGG and ultimately support the development and
utility of a liquid biopsy.Cell-free tumor DNA in circulation and
cerebrospinal fluid
Cell-free DNA (cfDNA) are short (approximately 160
base pair fragments of genetic material) and when
derived from a tumor are known as circulating tumor
DNA (ctDNA), which can be detected in the blood and
CSF from patients with cancer.37 These DNA contain
both genetic and epigenetic information revealing the
tumor site of origin and, importantly, specific DNA al-
terations (i.e., point mutations, specific methylation
patterns).37,38 However, ctDNA has a high turnover rate
because of its rapid clearance from the bloodstream,
which could make detecting it difficult in cases of low
tumor burden.
Beyond diagnostic utility, longitudinal ctDNA has the
potential to inform treatment monitoring and, in the era of
precision medicine, aid therapeutic predication. Currently,
in some diseases, such as melanoma, gastrointestinal, or
breast cancers, ctDNA is used as a metric for disease
progression, with higher levels correlating to an increased
disease burden or recurrence.39
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In adult high-grade glioma, ctDNA has been detected
in the blood and CSF. Studies investigating ctDNA have
focused on the detection of molecular aberrations from
known diagnostic, predictive, prognostic, or monitoring
values from the literature on adult tissue biomarkers.
These ctDNA targets include IDH1 mutations; EGFRvIII
mutation; loss of heterozygosity for 1p, 10q, 19q; and the
abnormal methylation of promoters (eg, O-6-
methylguanine-DNA methyltransferase) but are
currently limited to exploratory investigations and pro-
spective clinical utility testing.40-44
Tumor hemorrhage, biopsy, and neuroanatomical
location may challenge the sensitivity of ctDNA as a
diagnostic biomarker. For example, Wang et al. highlight
that proximity to CSF reservoirs was associated with
increased detection ctDNA in CSF.45 However, as the
field of precision medicine grows, the stage may be set for
the use of ctDNA as a companion diagnostic and pre-
dictive and monitoring biomarker. For example, the
detection of EGFRvIII mutation (therapeutic target of
interest) can be missed on tissue resection owing to het-
erogeneous expression but has been detected in the blood
as ctDNA.46
Furthermore, the authors report that 2 patients with
detectable preresection EGFRvIII ctDNA had undetect-
able levels after a gross total resection.46 Pathologic
variants of EGFR are more common in adult HGG than in
pHGG; however, EGFR mutations are present in pHGG
and efforts to leverage a molecularly defined lesion not
just for therapeutic proposes but also as a minimally
invasive biomarker of disease provide a valuable
example.Cell-free DNA in pediatric high-grade glioma
The rapidly advancing molecular subgrouping of
pHGG provides a rich landscape of candidate muta-
tions for the development of ctDNA biomarkers, and
the detection of ctDNA in the blood and CSF of pe-
diatric patients with HGG has been reported. Multiple
reports of H3K27M mutant cfDNA in CSF exist, this
prognostic biomarker is known to portend a poor
prognosis and to be common in midline gliomas, such
as DIPG.47 Diagnostic noninvasive biomarkers for
DIPG are highly desirable given that the disease is
sensitive to neuroanatomical location and concern for
harm with biopsy, and most patients are diagnosed
based on imaging features and history. However, a
growing number of centers are now safely performing
biopsies of these tumors,48 allowing for access to
molecularly defined clinical trials.
Recently, the detection of H3K27M has been reported
in the plasma of patients with DIPG and when correlatedwith CSF ctDNA and followed longitudinally, the
detectiont correlated with disease progression. The au-
thors suggested that the measurement of H3K27M ctDNA
could have diagnostic, prognostic, predictive, and moni-
toring biomarker potential; however, this has not been
prospectively studied. Oncogenic BRAFv600E mutations
are seen in pHGG, although more commonly in low-grade
gliomas, and hold the potential to be predictive, prog-
nostic, and monitoring biomarkers.
Although not yet reported in the blood of patients with
gliomas, the assessment of BRAFv600E cfDNA has been
used as a monitoring biomarker in pediatric patients with
Langerhans Cell Histocytosis (LCH).49 In this small
study, the measurement of BRAFv600E cfDNA corre-
lated with disease stage and treatment response regardless
of the treatment agents used.50 The oncogenic neuro-
trophic tyrosine receptor kinase (NTRK) fusion is present
in pHGG and although rare, NTRK is more commonly
found in children age <3 years.51 The recent tissue
agnostic approval of the pan-tropomyosin receptor kinase
inhibitor (TRK), loratrectinib, an inhibitor of the NTRK
fusion product, makes the noninvasive detection of
NTRK fusions an attractive biomarker.
The literature on adult gliomas measured NTRK
cfDNA as a monitoring biomarker of treatment response
and predictive biomarker of resistance mechanisms for
agents aimed at overcoming the mutational resistance
mechanism.52 Pediatric studies, including CNS tumors,
with next generation NTRK inhibitors are ongoing (e.g.,
NCT02650401) and include the measurement of ctDNA
as biologic correlates of disease. The continued prospec-
tive collection of ctDNA in clinical trials is needed to
fully appreciate the utility of ctDNA in pHGG. The
clinical development of ctDNA is an exciting tool for
pHGG and precision medicine; however, this biomaterial
currently falls short of capturing the robust dynamic
tumor biology present at the cellular level.Meaningful messengers: MicroRNA in adult high-
grade glioma
MicroRNAs (miRNAs) are small, 18 to 22 nucleotide
segments of single-stranded noncoding RNA. MiRNAs
function as regulators of posttranscriptional and trans-
lational processes by targeting specific messenger
RNAs.53,54 MiRNAs were first noted in 1993 with the
discovery of a novel gene regulation pathway.55 In 2004,
Takamizawa et al demonstrated that the let-7 family of
miRNAs held prognostic value in lung cancer, with
higher expression correlated to a more aggressive disease
state.56 In cancer, miRNAs are dysregulated and can act
as tumor suppressors or oncogenes depending on their
prescribed function. Now, unique miRNA expression
profiles have been linked to specific cancers, making
miRNAs not only an important effector of disease but also
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miRNAs has been documented in both pediatric and adult
HGG. Birks et al. analyzed the miRNA profiles of 24
pediatric CNS tumors and noted a distinct deregulation of
miRNA-129, miR-142-5p, and miR-25.57 Although
promising, the utility of miRNA in cancer therapeutics
and detection needs to be further validated before
becoming a common-place cancer detection strategy.
Small but mighty: Exosomes in adult high-grade
glioma
Exosomes are small membrane-bound vesicles ranging
from 50 to 140 nm and were first discovered in the late
1980s.58 Exosomes have come of age as promising ef-
fectors of the tumor microenvironment and liquid bio-
markers of disease diagnosis and prognosis. Once thought
to be a byproduct underlying a mechanism for transferrin
receptor elimination by red blood cells, we now know that
many different cell types extrude exosomes in normal
physiological conditions. Intravesicular cargo includes
proteins, DNA, RNA (including noncoding RNAs), and
various lipid species.59-61 The wide variety of exosome
cargo point to the functional relevance of exosomes in
intercellular communication. For example, exosomes
contain both cytosolic61 and membrane-bound proteins62
(cytoplasmic proteins that support vesicular biogenesis)
and membrane-bound proteins (eg, CD963 and CD6364)
that imply an immune function. Much of the lipid and
protein cargo is thought to reflect the metabolic state of
the cell of origin.61
Furthermore, exosomes are thought to mediate inter-
cellular communication within a microenvironment.65 In
cancer settings, exosomes are described to mediate
angiogenesis,66 establishment of the premetastatic niche,
and tumor progression.67 As a liquid biomarker, exo-
somes remain a promising prognostic or diagnostic ana-
lyte, carrying myriad miRNAs, with significant
differences seen between healthy controls and various
cancers, including glioblastoma,68,69 pancreatic,70,71
colorectal,72 lung,73 and breast74 cancer.
Exosomes function in high-grade glioma
Advances in understanding how exosomes shape HGG
are predominantly conducted in adult glioblastoma and
shed important insights into the exosome role in tumor
progression and its role as a biomarker for disease.68
Currently, studies focus on 3 primary areas: impact of
exosomes in shaping the tumor microenvironment, char-
acterization of exosome cargo, and use of exosomes as a
liquid biomarker.
Exosomes extruded from irradiated glioblastoma cells
alter migratory behaviors of recipient cells in culture,
indicating a role for exosomes in shaping the tumormicroenvironment.75 These exosomes carry cargo,
including connective tissue growth factor mRNA and
insulin-like growth factor binding protein, and support the
potential to affect tumor cell phenotypes or behaviors.
Untreated tumor cells extrude cargo with cell-signaling
components, notably farnesylated Ras found in
glioblastoma-derived exosomes.76
Furthermore, recent studies from an MD Anderson
group led by Dr Heimburger revealed that glioblastoma-
derived exosomes affect immunosuppression by targeting
tumor-associated monocytes driving differentiation to-
ward an immune-suppressive M2-macrophage fate, spe-
cifically elucidating the activation of the STAT3 pathway
in this population.77,78 Not only do exosomes harbor
effector molecules, they also harbor tumor-associated
proteins such as mutant forms of EGFR,79 IDH1,80 and
miR21.81 These studies, and other exosome-based bio-
markers of glioblastoma, are highlighted in a review by
Rennert et al82 focusing on adult glioma. A dearth of
studies have extended into pediatric brain tumors,
although miRNA that contain exosomes have been
documented.83 Exosome detection in CSF and blood84,85
highlight the potential impact of exosomes as biomarkers
of disease.
In adult disease, exosomes derived from different
subtypes of glioma contain a differential expression of
exosome biogenesis mRNA genes,86 which indicates that
a potential inequality in exosome extrusion may exist
across subtypes. Discrete omics are identified in adult
versus pediatric tumors,87 which further calls into ques-
tion how much of the glioblastoma-derived exosome
knowledge from adult disease will translate into pediatric
disease. A small handful of studies investigating exo-
somes in pediatric disease are beginning to provide in-
sights. Recently, miRNA-containing exosomes have been
documented in pediatric brain tumors,83 opening the field
for potential clinical trials with exosome analytes or the
development of exosomes as diagnostic agents for disease
progression.61Circulating cells: Circulating tumor cells,
circulating hybrid cells, clusters, and tumor-
associated immune cells
Circulating cells with the potential to provide infor-
mation on tumor state, including its pathology, hetero-
geneity, mutational burden, and predictive risk for disease
progression, remain a holy grail of liquid biopsies. To
date, a number of tumor-associated cell populations are
detectible in the peripheral blood of patients with cancer,
with the most noted being circulating tumor cells (CTCs),
which were first detected in 1869 in a patient with met-
astatic cancer.88 CTCs hold the promise of providing
temporal information of the evolving tumor in the form of
a noninvasive, liquid biopsy.
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value,89,90 genetic material,91 tumor phenotype (e.g.,
HER2 for breast cancer92), and a measure of tumor cell
heterogeneity.93 Once a barrier, new advances in the
isolation of CTCs has led to approval by the U.S. Food
and Drug Administration for the use of CTC enumeration
for clinical testing.89 Notably, the commercially available
CellSearch system94 relies on cytokeratin expression and
lack of CD45 expression and magnetic-based separation,
microfluidics systems that separate based on size,95 and
the Gilupi Cell Collector that extracts CTCs directly from
the bloodstream.96
Although promising, the use of CTCs for reliable
tumor monitoring has fallen short of expectations, largely
owing to the rarity of CTCs in peripheral blood. Reported
detectable ranges from 0.1 to 1 cell/mL are dependent on
tumor stage and tumor site.97 In addition, the use of
common epithelial proteins to identify CTCs may hamper
the ability to definitively enumerate tumor-associated
cells distinct from circulating epithelial cells.98 Finally,
inconsistency among reports on the efficacy and repro-
ducibility of CTCs as a biomarker for treatment response,
prognosis, and risk of relapse hamper strong reliance on
this biomarker.Circulating tumor cells in adult high-grade glioma
The use of CTCs for prognosis in glioblastoma is in its
infancy. The fact that patients with glioblastoma rarely
experience metastatic spread led to the concept that
glioblastoma is restricted to the brain. Subsequently, re-
ports of detectable glioblastoma metastatic growth in
organ-transplant recipients received from glioblastoma
donors challenged this notion.99,100 CTCs were first
identified in patients with glioblastoma in 2014.101 Glial
fibrillary acid protein-positive CTCs were identified in
20.6% of patients with glioblastoma and found to harbor
specific aberrations of the primary tumor, including
EGFR gene amplification or chromosome insertions or
deletions.
Consistent with CTCs identified in other organ sys-
tems, glioblastoma CTCs were rare and only detectible as
1 to 22 CTCs in 2.1  106 peripheral blood mononuclear
cells. Using a microfluidic approach to deplete blood cells
from peripheral blood specimens and thus isolating CTCs,
Sullivan et al reported that glioblastoma CTCs have
mesenchymal properties. In these studies 13 of 33 adult
patients with glioblastoma harbored CTCs.102 Further-
more, Gao et al. enhanced the detection of CTCs using a
novel fluorescence in situ hybridization-based approach
that allowed for the detection of CTCs in patients with all
7 subtypes of glioblastoma in 77% of patients studied.103
Most recently, in the British Journal of Cancer, tem-
poral analyses of 13 adult patients with glioblastoma
undergoing treatment were studied for the presence ofCTCs, identifying CTC clusters throughout the disease
progression, which suggests that CTCs may not travel the
bloodstream as solitary entities.104 This small handful of
reports highlights that the study of glioblastoma CTCs
lags far behind that of other organ systems. Although
glioblastoma CTC is nascent, currently all reported
studies of CTCs are in adult cancers. Pediatric glioblas-
toma provides a needed setting for the development of
noninvasive biomarkers for a treatment-resistant disease
with unappreciated evolution behaviors and unknown
susceptibilities.Developing the landscape of circulating cellullar
biomarkers
Although CTCs are the most well-studied circulating
cells in all cancers, including adult glioblastoma, other
circulating cells exist and hold value. A novel cancer cell
population derived from the fusion between tumor and
immune cells, circulating hybrid cells,105 were recently
identified in melanoma and pancreatic cancer. Circulating
hybrid cells outnumbered conventionally defined CTCs in
murine models of cancer and in human patients with
pancreatic cancer, which indicates a larger population of
tumor burden in peripheral blood than previously appre-
ciated. This revelation provides an opportunity to develop
a high-impact liquid biomarker.
In addition, cancer-associated macrophage-like cells106
or tumor epitope detection in monocytes,107 which are
immune cells with detectable apoptotic neoplastic cells
within their cytoplasm, have been reported in a variety of
cancers. Tumor-extrinsic biomarkers, such as circulating
immune signatures, may provide an immunomonitoring
opportunity that is important to the growing number of
immunooncology clinical trials.108 Taken together, the
myriad of cells in circulation offer a fertile ground for
temporal information of the evolving tumor and its
immunogenicity in the form of a noninvasive, liquid
biopsy.Conclusions
Major advances in technology to analyze circulating
cancer biomarkers primes the neuro-oncology field to
interrogate the liquid biome and develop noninvasive
analyses of disease for pHGG. The rarity of pHGG and
invasive nature of tumor biopsies hamper major advances
in understanding the disease, including disease initiation,
progression, and evolution. The development of the liquid
biome in pHGG (Table 1) holds promise to improve pa-
tient care through the identification of diagnostic, prog-
nostic, predictive, and monitoring biomarkers. The
discovery of circulating analytes capable of distinguishing
the MRI inaccuracy of pseudo- from true progression can
Table 1 Summary of circulating biomaterials with examples
Biomaterial Biosources Adult examples Pediatric examples
Serum Plasma CSF Urine
Protein x x x x VEGF30, MMPs/TIMPs31 VEGF33, bFGF33, CypA34,
DDAH134
Nucleic acids ctDNA x x x IDH139, EGFRvIII39, MGMT41, 1p/10q/19q
codeletion42
H3K27M46, BRAFv600E48
miRNA x x Yet to be reported miRNA-12956, miR-142-5p56,
miR-2556
Exosomes x x Ras75, EGFR78, IDH179, miR2180 Yet to be reported
Circulating
cells
CTCs x GFAP100 Yet to be reported
CHCs x Yet to be reported Yet to be reported
Abbreviations: bFGF Z basic fibroblast growth factor; CHCs Z circulating hybrid cells; CSF Z cerebrospinal fluid; CTCs Z circulating tumor
cells; ctDNAZ circulating tumor DNA; CypAZ cyclophilin A; DDAH1Z dimethylarginine dimethylaminohydrolase 1; GFAPZ glial fibrillary
acidic protein; IDH1Z isocitrate dehydrogenase 1; MGMTZ O-6-methylguanine-DNA methyltransferase; miRNAZmicro RNA; MMPZ matrix
metalloproteinase; TIMP Z tissue inhibitor of metalloproteinase; VEGF Z vascular endothelial growth factor.
Biosources, such as serum, plasma, CSF, and urine, can contain multiple biomaterials, including proteins, ctDNA, miRNA, exosomes, CTCs, and
CHCs.
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intervention.
Biomarkers capable of delineating pseudo- from true
responses will facilitate offering patient’s investigational
agents through clinical trials, perhaps earlier in the disease
progression course. Although many agents have failed to
show activity in early phase clinical trials, the deep and
rapid development of the biomolecular landscape of
pHGG is unearthing new potential targets.
Furthermore, cutting-edge technology for nucleic acid
isolation and sequencing, including cfDNA, RNA, and
microRNAs, makes the monitoring of mutations, cellular
behaviors, and evolution during treatment of pHGG
feasible and ultimately promises biologically relevant in-
sights in the mechanism of disease progression, treatment
resistance, and recurrence, as well as associated therapeutic
opportunities. The multidisciplinary care of pHGG pro-
vides a robust opportunity for each disciple to leverage
access to noninvasive patient biosources to advance
biomarker development in childhood CNS tumors.
Pediatric neuro-oncology as a field is poised to capi-
talize on the major advances in liquid biopsy. The
development of noninvasive disease analytes in pHGG
cannot be sidelined owing to the highly resistance,
recurrent, and lethal course of these tumors. However,
given that the disease course is abbreviated and treatment
responses are poor, coordinated efforts across institutions
must be engaged and consortiums must maintain focus in
collecting the necessary biomaterial to facilitate
advancing the treatment and management of pHGG. This
type of concerted effort, bringing advances in biomarker
knowledge in multianalytes, has the best chance to
develop new measures of disease that can affect disease
progression and change pHGG from a death sentence to a
managed disease.References
1. Ostrom QT, de Blank PM, Kruchko C, et al. Alex's Lemonade
Stand Foundation infant and childhood primary brain and central
nervous system tumors diagnosed in the United States in 2007-
2011. Neuro Oncol. 2015;16:x1-x36.
2. Liu M, Thakkar JP, Garcia CR, et al. National Cancer Database
analysis of outcomes in pediatric glioblastoma. Cancer Med. 2018;
7:1151-1159.
3. de Blank PM, Ostrom QT, Rouse C, et al. Years of life lived with
disease and years of potential life lost in children who die of cancer
in the United States, 2009. Cancer Med. 2015;4:608-619.
4. Jones C, Perryman L, Hargrave D. Paediatric and adult malignant
glioma: Close relatives or distant cousins? Nat Rev Clin Oncol.
2012;9:400-413.
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl
J Med. 2005;352:987-996.
6. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treat-
ment of high-grade gliomas in children: A report from the Child-
ren's Oncology Group. Neuro Oncol. 2011;13:317-323.
7. Jakacki RI, Cohen KJ, Buxton A, et al. Phase 2 study of concurrent
radiotherapy and temozolomide followed by temozolomide and
lomustine in the treatment of children with high-grade glioma: A
report of the Children's Oncology Group ACNS0423 study. Neuro
Oncol. 2016;18:1442-1450.
8. Gallitto M, Lazarev S, Wasserman I, et al. Role of radiation
therapy in the management of diffuse intrinsic pontine glioma: A
systematic review. Adv Radiat Oncol. 2019;4:520-531.
9. Shabason JE, Sutton D, Kenton O, Guttmann DM, Lustig RA, Hill-
Kayser C. Patterns of failure for pediatric glioblastoma multiforme
following radiation therapy. Pediatr Blood Cancer. 2016;63:1465-
1467.
10. Broniscer A. Past, present, and future strategies in the treatment of
high-grade glioma in children. Cancer Invest. 2006;24:77-81.
11. Veldhuijzen van Zanten SE, Baugh J, Chaney B, et al. Develop-
ment of the SIOPE DIPG network, registry and imaging repository:
A collaborative effort to optimize research into a rare and lethal
disease. J Neurooncol. 2017;132:255-266.
12. Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H,
Gottardo NG. Pediatric brain tumors: Innovative genomic
160 M.S. Dietz et al Advances in Radiation Oncology: MarcheApril 2020information is transforming the diagnostic and clinical landscape. J
Clin Oncol. 2015;33:2986-2998.
13. Mackay A, Burford A, Carvalho D, et al. Integrated molecular
meta-analysis of 1000 pediatric high-grade and diffuse intrinsic
pontine glioma. Cancer Cell. 2017;32:520-537.e5.
14. Jones C, Baker SJ. Unique genetic and epigenetic mechanisms
driving pediatric diffuse high-grade glioma. Nat Rev Cancer.
2014;14.
15. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations
in histone H3.3 and chromatin remodelling genes in paediatric
glioblastoma. Nature. 2012;482:226-231.
16. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3
alterations in pediatric diffuse intrinsic pontine gliomas and non-
brainstem glioblastomas. Nat Genet. 2012;44:251-253.
17. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A
and IDH1 define distinct epigenetic and biological subgroups of
glioblastoma. Cancer Cell. 2012;22:425-437.
18. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health
Organization classification of tumors of the central nervous system:
A summary. Acta Neuropathol. 2016;131:803-820.
19. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to
establish the glioma hypermethylator phenotype. Nature. 2012;
483:479-483.
20. Louis DN, Aldape K, Brat DJ, et al. Announcing cIMPACT-NOW:
The consortium to inform molecular and practical approaches to
CNS tumor taxonomy. Acta Neuropathol. 2017;133:1-3.
21. Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot
predict survival in childhood diffuse intrinsic pontine glioma. J
Neurooncol. 2008;86:313-319.
22. Poussaint TY, Kocak M, Vajapeyam S, et al. MRI as a central
component of clinical trials analysis in brainstem glioma: A report
from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol.
2011;13:417-427.
23. Wen PY, Macdonald DR, Reardon DA, et al. Updated response
assessment criteria for high-grade gliomas: Response assessment
in neuro-oncology working group. J Clin Oncol. 2010;28:1963-
1972.
24. Warren KE, Poussaint TY, Vezina G, et al. Challenges with
defining response to antitumor agents in pediatric neuro-oncology:
A report from the response assessment in pediatric neuro-oncology
(RAPNO) working group. Pediatr Blood Cancer. 2013;60:1397-
1401.
25. Jaspan T, Morgan PS, Warmuth-Metz M, et al. Response assess-
ment in pediatric neuro-oncology: Implementation and expansion
of the RANO criteria in a randomized phase II trial of pediatric
patients with newly diagnosed high-grade gliomas. AJNR Am J
Neuroradiol. 2016;37:1581-1587.
26. Li Y, Ali S, Clarke S, et al. Bevacizumab in recurrent glioma:
patterns of treatment failure and implications. Brain Tumor Res
Treat. 2017;5:1-9.
27. Bonner ER, Bornhorst M, Packer RJ, Nazarian J. Liquid biopsy for
pediatric central nervous system tumors. NPJ Precis Oncol. 2018;
2:29.
28. Maes E, Mertens I, Valkenborg D, Pauwels P, Rolfo C,
Baggerman G. Proteomics in cancer research: Are we ready for
clinical practice? Crit Rev Oncol Hematol. 2015;96:437-448.
29. Stone MJ, Frendel EP. The clinical spectrum of light chain
myeloma. A study of 35 patients with special reference to the
occurrence of amyloidosis. Am J Med. 1975;58:601-619.
30. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker
discovery and validation. Transl Cancer Res. 2015;4:256-269.
31. Carlsson A, Persson O, Ingvarsson J, et al. Plasma proteome
profiling reveals biomarker patterns associated with prognosis and
therapy selection in glioblastoma multiforme patients. Proteomics
Clin Appl. 2010;4:591-602.
32. Crocker M, Ashley S, Giddings I, et al. Serum angiogenic profile
of patients with glioblastoma identifies distinct tumor subtypes andshows that TIMP-1 is a prognostic factor. Neuro Oncol. 2011;13:
99-108.
33. Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T.
Liquid biopsies in patients with diffuse glioma. Acta Neuropathol.
2015;129:849-865.
34. Sobol-Milejska G, Mizia-Malarz A, Musiol K, et al. Serum levels of
vascular endothelial growth factor and basic fibroblast growth factor
in children with brain tumors. Adv Clin Exp Med. 2017;26:571-575.
35. Saratsis AM, Yadavilli S, Magge S, et al. Insights into pediatric
diffuse intrinsic pontine glioma through proteomic analysis of ce-
rebrospinal fluid. Neuro Oncol. 2012;14:547-560.
36. Spreafico F, Bongarzone I, Pizzamiglio S, et al. Proteomic analysis
of cerebrospinal fluid from children with central nervous system
tumors identifies candidate proteins relating to tumor metastatic
spread. Oncotarget. 2017;8:46177-46190.
37. Donaldson J, Park BH. Circulating tumor DNA: Measurement and
clinical utility. Annu Rev Med. 2018;69:223-234.
38. Neumann MHD, Bender S, Krahn T, Schlange T. ctDNA and
CTCs in liquid biopsy - Current status and where we need to
progress. Comput Struct Biotechnol J. 2018;16:190-195.
39. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating
tumor DNA in early- and late-stage human malignancies. Sci
Transl Med. 2014;6:224ra24.
40. Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM,
Zheng PP. Circulating glioma biomarkers. Neuro Oncol. 2015;17:
343-360.
41. Martinez-Ricarte F, Mayor R, Martínez-Sáez E, et al. Molecular
diagnosis of diffuse gliomas through sequencing of cell-free
circulating tumor DNA from cerebrospinal fluid. Clin Cancer
Res. 2018;24:2812-2819.
42. Rivera AL, Pelloski CE, Gilbert MR, et al. MGMT promoter
methylation is predictive of response to radiotherapy and prog-
nostic in the absence of adjuvant alkylating chemotherapy for
glioblastoma. Neuro Oncol. 2010;12:116-121.
43. Staedtke V, Dzaye ODA, Holdhoff M. Actionable molecular bio-
markers in primary brain tumors. Trends Cancer. 2016;2:338-349.
44. Thon N, Kreth S, Kreth FW. Personalized treatment strategies in
glioblastoma: MGMT promoter methylation status. Onco Targets
Ther. 2013;6:1363-1372.
45. Wang Y, Springer S, Zhang M, et al. Detection of tumor-derived
DNA in cerebrospinal fluid of patients with primary tumors of
the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112:
9704-9709.
46. Salkeni MA, Zarzour A, Ansay TY, et al. Detection of EGFRvIII
mutant DNA in the peripheral blood of brain tumor patients. J
Neurooncol. 2013;115:27-35.
47. Huang TY, Piunti A, Lulla RR, et al. Detection of Histone H3
mutations in cerebrospinal fluid-derived tumor DNA from chil-
dren with diffuse midline glioma. Acta Neuropathol Commun.
2017;5:28.
48. Gupta N, Goumnerova LC, Manley P, et al. Prospective feasibility
and safety assessment of surgical biopsy for patients with newly
diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018;20:
1547-1555.
49. Panditharatna E, Kilburn LB, Aboian MS, et al. Clinically relevant
and minimally invasive tumor surveillance of pediatric diffuse
midline gliomas using patient-derived liquid biopsy. Clin Cancer
Res. 2018;24:5850-5859.
50. Héritier S, Hélias-Rodzewicz Z, Lapillonne H, et al. Circulating
cell-free BRAF(V600E) as a biomarker in children with Langer-
hans cell histiocytosis. Br J Haematol. 2017;178:457-467.
51. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of
diffuse intrinsic pontine glioma and pediatric nonbrainstem high-
grade glioma. Nat Genet. 2014;46:444-450.
52. Russo M, Misale S, Wei G, et al. Acquired resistance to the TRK
inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016;6:
36-44.
Advances in Radiation Oncology: MarcheApril 2020 Liquid biopsy in pediatric high-grade gliomas 16153. Ono S, Lam S, Nagahara M, Hoon DS. Circulating microRNA
biomarkers as liquid biopsy for cancer patients: Pros and cons of
current assays. J Clin Med. 2015;4:1890-1907.
54. Peng Y, Croce CM. The role of MicroRNAs in human cancer.
Signal Transduct Target Ther. 2016;1:15004.
55. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic
gene lin-4 encodes small RNAs with antisense complementarity to
lin-14. Cell. 1993;75:843-854.
56. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression
of the let-7 microRNAs in human lung cancers in association with
shortened postoperative survival. Cancer Res. 2004;64:3753-3756.
57. Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R,
Foreman NK. Survey of MicroRNA expression in pediatric brain
tumors. Pediatr Blood Cancer. 2011;56:211-216.
58. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle
formation during reticulocyte maturation. Association of plasma
membrane activities with released vesicles (exosomes). J Biol
Chem. 1987;262:9412-9420.
59. Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in
exosomes: A novel biomarker in cancer detection. Cell Res. 2014;
24:766-769.
60. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO.
Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat Cell Biol. 2007;
9:654-659.
61. Rajagopal C, Harikumar KB. The origin and functions of exo-
somes in cancer. Front Oncol. 2018;8:66.
62. Tamai K, Tanaka N, Nakano T, et al. Exosome secretion of den-
dritic cells is regulated by Hrs, an ESCRT-0 protein. Biochem
Biophys Res Commun. 2010;399:384-390.
63. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O,
Geuze HJ. Selective enrichment of tetraspan proteins on the in-
ternal vesicles of multivesicular endosomes and on exosomes
secreted by human B-lymphocytes. J Biol Chem. 1998;273:20121-
20127.
64. Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes
expressing CD63 and caveolin-1 in plasma of melanoma patients.
PLoS One. 2009;4:e5219.
65. Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate
stromal mobilization of autocrine Wnt-PCP signaling in breast
cancer cell migration. Cell. 2012;151:1542-1556.
66. Maji S, Chaudhary P, Akopova I, et al. Exosomal annexin II
promotes angiogenesis and breast cancer metastasis. Mol Cancer
Res. 2017;15:93-105.
67. Zhang L, Zhang S, Yao J, et al. Microenvironment-induced PTEN
loss by exosomal microRNA primes brain metastasis outgrowth.
Nature. 2015;527:100-104.
68. Gourlay J, Morokoff AP, Luwor RB, Zhu HJ, Kaye AH, Stylli SS.
The emergent role of exosomes in glioma. J Clin Neurosci. 2017;
35:13-23.
69. Shao H, Chung J, Lee K, et al. Chip-based analysis of exosomal
mRNA mediating drug resistance in glioblastoma. Nat Commun.
2015;6:6999.
70. Armstrong EA, Beal EW, Chakedis J, et al. Exosomes in pancre-
atic cancer: From early detection to treatment. J Gastrointest Surg.
2018;22:737-750.
71. Li W, Li C, Zhou T, et al. Role of exosomal proteins in cancer
diagnosis. Mol Cancer. 2017;16:145.
72. Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exo-
somal microRNAs as biomarkers of colon cancer. PLoS One.
2014;9:e92921.
73. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD,
Kloecker GH. Exosomal microRNA: A diagnostic marker for lung
cancer. Clin Lung Cancer. 2009;10:42-46.
74. Eichelser C, Stückrath I, Müller V, et al. Increased serum levels of
circulating exosomal microRNA-373 in receptor-negative breast
cancer patients. Oncotarget. 2014;5:9650-9663.75. Arscott WT, Tandle AT, Zhao S, et al. Ionizing radiation and
glioblastoma exosomes: Implications in tumor biology and cell
migration. Transl Oncol. 2013;6:638-648.
76. Luhtala N, Aslanian A, Yates JR 3rd, Hunter T. Secreted glio-
blastoma nanovesicles contain intracellular signaling proteins and
active Ras incorporated in a farnesylation-dependent manner. J
Biol Chem. 2017;292:611-628.
77. de Vrij J, Maas SL, Kwappenberg KM, et al. Glioblastoma-derived
extracellular vesicles modify the phenotype of monocytic cells. Int
J Cancer. 2015;137:1630-1642.
78. Gabrusiewicz K, Li X, Wei J, et al. Glioblastoma stem cell-derived
exosomes induce M2 macrophages and PD-L1 expression on
human monocytes. Oncoimmunology. 2018;7:e1412909.
79. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of
the oncogenic receptor EGFRvIII by microvesicles derived from
tumor cells. Nat Cell Biol. 2008;10:619-624.
80. Cheng C, Chen YH, Lennox KA, Behlke MA, Davidson BL.
In vivo SELEX for identification of brain-penetrating aptamers.
Mol Ther Nucleic Acids. 2013;2:e67.
81. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles
transport RNA and proteins that promote tumour growth and
provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470-1476.
82. Rennert RC, Hochberg FH, Carter BS. ExRNA in biofluids
as biomarkers for brain tumors. Cell Mol Neurobiol. 2016;36:
353-360.
83. T}uzesi Á, Kling T, Wenger A, et al. Pediatric brain tumor cells
release exosomes with a miRNA repertoire that differs from exo-
somes secreted by normal cells. Oncotarget. 2017;8:90164-90175.
84. Gonda DD, Akers JC, Kim R, et al. Neuro-oncologic applications
of exosomes, microvesicles, and other nano-sized extracellular
particles. Neurosurgery. 2013;72:501-510.
85. Shi R, Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from
cerebrospinal fluids associated with poor prognosis and tumor
recurrence of glioma patients. Oncotarget. 2015;6:26971-26981.
86. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic
analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and
NF1. Cancer Cell. 2010;17:98-110.
87. Ma X, Liu Y, Liu Y, et al. Pan-cancer genome and transcriptome
analyses of 1,699 paediatric leukaemias and solid tumours. Nature.
2018;555:371-376.
88. Apostolou P, Papadimitriou M, Papapsotiriou I. Stemness gene
profiles of circulating tumor cells. J Cancer Ther. 2017;9.
89. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells,
disease progression, and survival in metastatic breast cancer. N
Engl J Med. 2004;351:781-791.
90. O'Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG,
Terstappen LW. Multigene reverse transcription-PCR profiling of
circulating tumor cells in hormone-refractory prostate cancer. Clin
Chem. 2004;50:826-835.
91. Boral D, Vishnoi M, Liu HN, et al. Molecular characterization of
breast cancer CTCs associated with brain metastasis. Nat Commun.
2017;8:196.
92. Hayes DF, Thor AD. c-erbB-2 in breast cancer: Development of a
clinically useful marker. Semin Oncol. 2002;29:231-245.
93. Brouwer A, De Laere B, Peeters D, et al. Evaluation and conse-
quences of heterogeneity in the circulating tumor cell compart-
ment. Oncotarget. 2016;7:48625-48643.
94. Andreopoulou E, Yang LY, Rangel KM, et al. Comparison of assay
methods for detection of circulating tumor cells in metastatic breast
cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus
Veridex CellSearch system. Int J Cancer. 2012;130:1590-1597.
95. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor
cells using a microvortex-generating herringbone-chip. Proc Natl
Acad Sci U S A. 2010;107:18392-18397.
96. Theil G, Fischer K, Weber E, et al. The use of a new Cell-
Collector to isolate circulating tumor cells from the blood of
162 M.S. Dietz et al Advances in Radiation Oncology: MarcheApril 2020patients with different stages of prostate cancer and clinical
outcomesdA proof-of-concept Study. PLoS One. 2016;11:
e0158354.
97. de Wit S, van Dalum G, Lenferink AT, et al. The detection of
EpCAM(þ) and EpCAM(-) circulating tumor cells. Sci Rep. 2015;
5:12270.
98. Bhan I, Mosesso K, Goyal L, et al. Detection and analysis of
circulating epithelial cells in liquid biopsies from patients with
liver disease. Gastroenterology. 2018;155:2016-2018.e11.
99. Frank S, Müller J, Bonk C, Haroske G, Schackert HK,
Schackert G. Transmission of glioblastoma multiforme through
liver transplantation. Lancet. 1998;352:31.
100. Jonas S, Bechstein WO, Lemmens HP, Neuhaus R,
Thalmann U, Neuhaus P. Liver graft-transmitted glioblastoma
multiforme. A case report and experience with 13 multiorgan
donors suffering from primary cerebral neoplasia. Transpl Int.
1996;9:426-429.
101. Muller C, Holtschmidt J, Auer M, et al. Hematogenous dissemi-
nation of glioblastoma multiforme. Sci Transl Med. 2014;6:
247ra101.102. Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in
circulation are enriched for mesenchymal gene expression. Cancer
Discov. 2014;4:1299-1309.
103. Gao F, Cui Y, Jiang H, et al. Circulating tumor cell is a common
property of brain glioma and promotes the monitoring system.
Oncotarget. 2016;7:71330-71340.
104. Krol I, Castro-Giner F,MaurerM, et al.Detection of circulating tumour
cell clusters in human glioblastoma. Br J Cancer. 2018;119:487-491.
105. Gast CE, Silk AD, Zarour L, et al. Cell fusion potentiates tumor
heterogeneity and reveals circulating hybrid cells that correlate
with stage and survival. Sci Adv. 2018;4:eaat7828.
106. Adams DL, Martin SS, Alpaugh RK, et al. Circulating giant
macrophages as a potential biomarker of solid tumors. Proc Natl
Acad Sci U S A. 2014;111:3514-3519.
107. Jansen N, Coy JF. Diagnostic use of epitope detection in mono-
cytes blood test for early detection of colon cancer metastasis.
Future Oncol. 2013;9:605-609.
108. Müller S, Agnihotri S, Shoger KE, et al. Peptide vaccine immu-
notherapy biomarkers and response patterns in pediatric gliomas.
JCI Insight. 2018;3.
